Report an Adverse Event
We take reports of side effects and other adverse events seriously and have a dedicated pharmacovigilance team that is focused on ensuring the safety of our medicines.
Rare genetic conditions often come with uncommon challenges, and we’re here to help. Learn more about the programs and practices we have in place to help support patient communities, access and safety.
Patient safety is our most important priority and central to everything we do across the entire lifecycle, from research and development and manufacturing to the ongoing monitoring of our medicines. We maintain robust processes to identify, evaluate and address potential safety concerns, ensuring our therapies meet rigorous quality and regulatory standards.
We take reports of side effects and other adverse events seriously and have a dedicated pharmacovigilance team that is focused on ensuring the safety of our medicines.
We carefully review any reports of potential issues related to the quality, safety and efficacy of our products. Please let us know of any concerns so we can evaluate and address them in accordance with regulatory guidelines.
We created the BioMarin RareConnections™ patient support program to help navigate the difficulties of managing serious and rare genetic conditions through a wide array of product support services throughout an individual’s treatment journey.
Our dedicated and experienced RareConnections team members will provide guidance on how to gain access to BioMarin medicines by:
27 Students Supported since 2018
Our RARE Scholars program provides financial support to U.S. college students living with, or caring for someone living with, one of several rare genetic conditions – achondroplasia, Batten disease, mucopolysaccharidosis (MPS) or phenylketonuria (PKU). Since its inception in 2018, the program has awarded nearly $200,000 to 27 students who have demonstrated exceptional leadership and engagement in school and community activities.
The application period for the 2026-27 academic year is closed. We will begin accepting applications for the 2027-28 academic year in February 2027.
A key pillar of our approach to corporate giving is providing funding to patient advocacy groups that support the communities we serve. We focus on donating to groups and programs that empower patients and help increase disease awareness.
